Differences in the total body clearance of lead compounds in the rat and mouse: Impact on pharmacokinetic screening strategy

Xenobiotica

Volumn 38, Issue 6, 2008, Pages 605-619

  McIntyre, T A ^a   Han, C ^a   Xiang, H ^a   Bambal, R ^a   Davis, C B ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Clearance; Intrinsic clearance; Lead optimization; Mouse; Protein binding; Rat

Indexed keywords

LEAD;

ANIMAL CELL; ARTICLE; DOG; LIVER CELL; LIVER MICROSOME; MALE; MONKEY; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA PROTEIN BINDING; RAT; RODENT;

ANIMALS; HEPATOCYTES; LEAD; MALE; METABOLIC CLEARANCE RATE; MICE; MICROSOMES, LIVER; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY;

CANIS FAMILIARIS; RATTUS; RODENTIA;

EID: 45849088093     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802001834     Document Type: Article

References (15)

1. Banker MJ, Clark TH, Williams JA. 2003. Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. Journal of Pharmaceutical Science 92:967-974.
2. Clarke SE, Jeffrey P. 2001. Utility of metabolic stability screening: Comparison of in vitro and in vivo clearance. Xenobiotica 31:591-598.
3. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 10:1093-1095.
4. Evans CA, Jolivette LJ, Nagilla R, Ward KW. 2006. Extrapolation of preclinical pharmacokinetics and molecular feature analysis of 'discovery-like' molecules to predict human pharmacokinetics. Drug Metabolism and Disposition 34:1255-1265.
5. Kameoka N, Nimura Y, Sato T, Kato M, Yasui A, Kondo S. 1996. Postprandial responses of liver blood flow prior to and following hepatectomy in conscious dogs. Journal of Surgical Research 61:437-443.
6. Kelland LR. 2004. 'Of mice and men': Values and liabilities of the athymic nude mouse model in anticancer drug development. European Journal of Cancer 40:827-836.
7. Kurosawa M, Unno T, Yoshihiro AY, Yoneda M. 2002. Neural regulation of hepatic blood flow in rats: An in vivo study. Neuroscience Letters 321:145-148.
8. Mahmood I, Sahajwalla C. 2002. Interspecies scaling of biliary excreted drugs. Journal of Pharmaceutical Science 91:1908-1914.
9. Obach RS. 1999. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metabolism and Disposition 27:1350-1359.
10. Royo F, Carlsson H-E, Mayo S, Hau J. 2004. Impact of chronic catheterization and automated blood sampling (Accusampler) on serum coritcosterone and fecal immunoreactive corticosterone metabolites and immunoglobulin A in male rats. Journal of Endocrinology 180:145-153.
11. Shiran MR, Proctor NJ, Howgate EM, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2006. Prediction of metabolic drug clearance in humans: In vitro-in vivo extrapolation vs. allometric scaling. Xenobiotica 36:567-580.
12. Tang H, Hussain A, Leal M, Mayersohn M, Fluhler E. 2007. Interspecies prediction of human drug clearance based on scaling data from one or two animal species. Drug Metabolism and Disposition 35:1886-1893.
13. Tomaszewski JE. 2004. Multi-species toxicology approaches for oncology drugs: The US perspective. European Journal of Cancer 40:907-913.
14. Woo S, Jusko WJ. 2007. Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin. Drug Metabolism and Disposition 35:1672-1678.
15. Xiang H, McSurdy-Freed J, Moorthy GS, Hugger E, Bambal R, Han C, Ferrer S, Gargallo D, Davis CB. 2006. Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. Journal of Pharmaceutical Science 95:2657-2672.